

Table 1 Demographic, clinical, and neuroimaging characteristics across diagnostic groups

	AD/MCI (N=126) Mean (SD)	ALS (N = 40) Mean (SD)	FTD (N = 52) Mean (SD)	PD (N = 140) Mean (SD)	CVD (N = 155) Mean (SD)	Effect size η^2/V	F/χ^2, <i>p</i>-value
Age (years)	71.03 (8.16)	61.98 (8.74)	67.81 (7.12)	67.94 (6.34)	69.35 (7.36)	$\eta^2 = 0.09$	$F_{(4,508)} = 12.18, p < 0.001^a$
Sex (F:M) (% F)	57:69 (45.2)	16:24 (40.0)	19:33 (36.5)	31:109 (22.1)	49:106 (31.6)	$V = 0.18$	$\chi^2 (4) = 17.11, p = 0.002$
Education (years)	15.23 (3.08)	13.83 (2.88)	13.89 (2.73)	15.49 (2.73)	14.69 (2.88)	$\eta^2 = 0.04$	$F_{(4,508)} = 5.09, p = 0.001^b$
MoCA total score	22.67 (2.99)	25.46 (2.83)	21.48 (3.96)	25.84 (2.57)	25.29 (2.99)	$\eta^2 = 0.22$	$F_{(4,507)} = 12.18, p < 0.001^c$
ADLs	98.15 (4.59)	87.50 (13.95)	87.58 (15.65)	96.56 (7.34)	98.32 (5.42)	$\eta^2 = 0.19$	$F_{(4,483)} = 27.92, p < 0.001^d$
iADLs	85.28 (17.29)	78.27 (21.67)	60.99 (27.70)	89.73 (14.06)	91.13 (14.21)	$\eta^2 = 0.21$	$F_{(4,474)} = 32.05, p < 0.001^e$
<i>Vascular Risk Factors, n (% yes)</i>							
Hypertension	34 (64.2)	10 (71.4)	19 (70.4)	47 (69.1)	113 (83.7)	$V = 0.19$	$\chi^2 (4) = 10.46, p = 0.036$
Diabetes	25 (34.2)	2 (10.5)	8 (27.6)	13 (19.1)	34 (26.2)	$V = 0.14$	$\chi^2 (4) = 6.69, p = 0.159$
High Cholesterol	58 (79.5)	12 (63.2)	27 (93.1)	57 (83.8)	121 (93.1)	$V = 0.24$	$\chi^2 (4) = 17.94, p = 0.001$
Smoking	67 (53.2)	22 (55.0)	28 (53.8)	58 (41.4)	84 (54.2)	$V = 0.11$	$\chi^2 (4) = 6.37, p = 0.173$
<i>NPI-Q</i>	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)		
NPI-Q total severity score	3.67 (3.96)	3.08 (3.68)	8.08 (6.24)	3.51 (3.92)	3.16 (3.88)	$\eta^2 = 0.11$	$F_{(4,469)} = 14.00, p < 0.001^f$
NPI-Q caregiver distress score	4.12 (5.01)	3.74 (5.29)	9.00 (9.18)	4.05 (5.69)	3.55 (5.34)	$\eta^2 = 0.07$	$F_{(4,461)} = 8.28, p < 0.001^g$
<i>Neuropsychiatric Subsyndromes</i>	Mean (SE)	Mean (SE)	Mean (SE)	Mean (SE)	Mean (SE)		
Affective	0.81 (0.11)	0.70 (0.18)	1.35 (0.16)	0.86 (0.10)	0.57 (0.10)	$\eta^2 = 0.04$	$F_{(4,486)} = 4.46, p = 0.002^h$
Apathy	0.86 (0.11)	0.76 (0.19)	2.14 (0.17)	0.76 (0.11)	0.68 (0.10)	$\eta^2 = 0.11$	$F_{(4,486)} = 14.53, p < 0.001^i$
Hyperactivity	1.49 (0.18)	0.98 (0.31)	3.41 (0.27)	0.86 (0.17)	1.27 (0.16)	$\eta^2 = 0.12$	$F_{(4,486)} = 17.09, p < 0.001^j$
Psychosis	0.48 (0.10)	0.43 (0.16)	1.39 (0.15)	1.01 (0.09)	0.60 (0.09)	$\eta^2 = 0.08$	$F_{(4,486)} = 10.45, p < 0.001^k$
<i>Regional WMH (mm³)†</i>	Adjusted Mean (SE)	Adjusted Mean (SE)	Adjusted Mean (SE)	Adjusted Mean (SE)	Adjusted Mean (SE)		
Frontal	1508.59 (296.13)	1792.83 (535.23)	1797.59 (455.46)	1957.33 (277.74)	3744.89 (263.99)	$\eta^2 = 0.08$	$F_{(4,507)} = 10.37, p < 0.001^l$
Parietal	1090.54 (335.25)	1942.71 (605.93)	1401.15 (515.62)	1715.61 (314.43)	3748.51 (298.86)	$\eta^2 = 0.09$	$F_{(4,507)} = 13.19, p < 0.001^m$
Occipital	655.97 (74.45)	750.73 (134.57)	599.54 (114.51)	759.25 (69.83)	900.43 (66.37)	$\eta^2 = 0.02$	$F_{(4,507)} = 2.19, p = 0.069$
Temporal	525.24 (94.64)	644.06 (171.05)	599.86 (145.56)	664.23 (88.76)	1245.17 (84.37)	$\eta^2 = 0.07$	$F_{(4,507)} = 9.57, p < 0.001^n$
BGT	82.59 (24.51)	69.62 (44.30)	118.05 (37.69)	181.31 (23.99)	267.43 (21.85)	$\eta^2 = 0.09$	$F_{(4,507)} = 12.55, p < 0.001^o$

AD, Alzheimer’s disease; ADLs, Activities of Daily Living; ALS, Amyotrophic lateral sclerosis; BGT, Basal Ganglia/Thalamus; CVD, Cerebrovascular disease; FTD, Frontotemporal disease; iADLs, Instrumental Activities of Daily Living; MCI, Mild cognitive impairment; MoCA, Montreal Cognitive Assessment; NPI-Q, Neuropsychiatric Symptoms Inventory Questionnaire; PD, Parkinson’s disease.

^a ALS < AD/MCI ($p < 0.001$), FTD ($p = 0.002$), PD ($p < 0.001$), and CVD ($p < 0.001$); PD < AD/MCI ($p = 0.007$).

^b FTD < AD/MCI ($p = 0.047$) and PD ($p = 0.007$); ALS < PD ($p = 0.014$).

^c AD/MCI < ALS, PD, and CVD ($p < 0.001$); FTD < ALS, PD and CVD ($p < 0.001$).

^d ALS < AD/MCI, PD, and CVD ($p < 0.001$); FTD < AD/MCI, PD , and CVD ($p < 0.001$)

^e ALS < PD ($p = 0.003$) and CVD ($p < 0.001$); FTD < AD/MCI, ALS, PD, and CVD ($p < 0.001$).

^f FTD > AD/MCI, ALS, PD, and CVD ($p < 0.001$).

^g FTD > AD/MCI, PD, and CVD ($p < 0.001$), FTD > ALS ($p = 0.001$).

^h FTD > CVD ($p < 0.001$).

ⁱ FTD > AD/MCI, ALS, PD, and CVD ($p < 0.001$).

^j FTD > AD/MCI, ALS, PD, and CVD ($p < 0.001$).

^k FTD > AD/MCI, ALS, and CVD ($p < 0.001$); PD > AD/MCI ($p = 0.001$), ALS ($p = 0.020$), and CVD ($p = 0.011$).

^l CVD > AD/MCI and PD ($p < 0.001$); CVD > ALS ($p = 0.004$).

^m CVD > AD/MCI, ALS, and PD ($p < 0.001$); CVD > FTD ($p = 0.001$).

ⁿ CVD > AD/MCI ($p < 0.001$), ALS ($p = 0.002$), FTD ($p = 0.013$), and PD ($p = 0.005$).

^o CVD > AD/MCI ($p < 0.001$), ALS ($p = 0.003$), and FTD ($p = 0.023$); PD > AD/MCI ($p < 0.001$).

η^2 = Partial Eta Squared

V = Cramer’s V

† controlled for age

Table 2 Frequency of NPS across groups

NPS <i>n</i> (% yes)	AD/MCI	ALS	FTD	PD	CVD	χ^2 , <i>p</i> -value
Delusions	10 (8.7)	1 (2.5)	7 (13.7)	4 (2.9)	11 (7.6)	χ^2 (4) = 9.12, <i>p</i> = 0.058 [‡]
Hallucinations	5 (4.3)	1 (2.5)	2 (3.9)	13 (9.5)	3 (2.1)	χ^2 (4) = 9.33, <i>p</i> = 0.053 [‡]
Agitation/Aggression	33 (28.2)	9 (22.5)	20 (39.2)	24 (17.4)	37 (25.5)	χ^2 (4) = 10.54, <i>p</i> = 0.032*
Depression/Dysphoria	38 (32.5)	15 (37.5)	18 (36.0)	52 (37.7)	38 (26.2)	χ^2 (4) = 4.98, <i>p</i> = 0.289
Anxiety	30 (25.6)	7 (17.5)	24 (47.1)	30 (21.7)	22 (15.2)	χ^2 (4) = 22.94, <i>p</i> < 0.001***
Euphoria/Elation	6 (5.1)	2 (5.0)	8 (15.7)	4 (2.9)	5 (3.4)	χ^2 (4) = 14.03, <i>p</i> = 0.007**
Apathy/Indifference	44 (38.3)	11 (27.5)	28 (56.0)	32 (23.2)	33 (22.8)	χ^2 (4) = 26.43, <i>p</i> < 0.001***
Disinhibition	27 (23.1)	3 (7.5)	22 (44.0)	17 (12.3)	21 (14.5)	χ^2 (4) = 31.62, <i>p</i> < 0.001***
Irritability/Lability	44 (37.9)	9 (22.5)	30 (58.8)	38 (27.5)	55 (38.2)	χ^2 (4) = 19.48, <i>p</i> < 0.001***
Aberrant motor behaviour	15 (12.8)	5 (12.8)	16 (31.4)	7 (5.1)	12 (8.3)	χ^2 (4) = 27.68, <i>p</i> < 0.001***
Appetite/eating abnormalities	32 (28.1)	16 (41.0)	29 (56.9)	38 (27.5)	33 (22.8)	χ^2 (4) = 23.79, <i>p</i> < 0.001***
Night time behaviour	26 (22.8)	10 (26.3)	28 (54.9)	73 (52.9)	49 (34.0)	χ^2 (4) = 33.38, <i>p</i> < 0.001***

AD/MCI; AD, Alzheimer’s disease; ALS, Amyotrophic lateral sclerosis; CVD, Cerebrovascular disease; FTD, Frontotemporal disease; MCI, Mild cognitive impairment; NPS, Neuropsychiatric symptoms; PD, Parkinson’s disease.

[‡] trending
****p* < 0.001
***p* < 0.01
**p* < 0.05

Table 3 Group comparison results for significant NPS

NPS	<i>p</i> -value
Agitation	
FTD (39.2%) > PD (17.4%)	0.003
Anxiety	
FTD (47.1%) > PD (21.7%)	0.001
FTD (47.1%) > ALS (17.5%)	0.004
FTD (47.1%) > CVD (15.2%)	< 0.001
AD/MCI (25.6%) > CVD (15.2%)	0.043†
Apathy	
FTD (56.0%) > PD (23.2%)	< 0.001
FTD (56.0%) > ALS (27.5%)	0.001
FTD (56.0%) > CVD (22.8%)	< 0.001
AD/MCI (38.3%) > PD (23.2%)	0.013†
AD/MCI (38.3%) > CVD (22.8%)	0.009†
Appetite	
FTD (56.9%) > AD/MCI (28.1%)	< 0.001
FTD (56.9%) > PD (27.5%)	< 0.001
FTD (56.9%) > CVD (22.8%)	< 0.001
ALS (41.0%) > CVD (22.8%)	0.026†
Disinhibition	
FTD (44.0%) > CVD (14.5%)	< 0.001
FTD (44.0%) > PD (12.3%)	< 0.001
FTD (44.0%) > ALS (7.5%)	< 0.001
AD/MCI (23.1%) > PD (12.3%)	0.030†
AD/MCI (23.1%) > ALS (7.5%)	0.036†
Euphoria	
FTD (15.7%) > PD (2.9%)	< 0.001
Irritability	

FTD (58.8%) > PD (27.5%)	< 0.001
FTD (58.8%) > ALS (22.5%)	< 0.001
Aberrant motor behaviour	
FTD (31.4%) > CVD (8.3%)	< 0.001
FTD (31.4%) > PD (5.1%)	< 0.001
AD/MCI (12.8%) > PD (5.1%)	0.042†
Night time behaviours	
FTD (54.9%) > AD/MCI (22.8%)	< 0.001
PD (52.9%) > ADMCI (22.8%)	< 0.001

AD/MCI; AD, Alzheimer’s disease; ALS, Amyotrophic lateral sclerosis; CVD, Cerebrovascular disease; FTD, Frontotemporal disease; MCI, Mild cognitive impairment; NPS, Neuropsychiatric symptoms; PD, Parkinson’s disease.

Comparisons calculated according to Fisher’s Exact Test

† did not survive correction for multiple comparisons
(0.05/10 = 0.005)

Table 4 Demographics and summary for all elastic net and PLSc analyses

N = 490	Female	Male
ADMCI	52	65
ALS	16	23
FTD	19	32
PD	31	107
CVD	46	99

Mean age = 68.67, Median age = 68.78, Min/Max age = 40.12/87.80.
Mean MoCA = 24.40, Median MoCA = 25.0, Min/Max MoCA = 13.00/30.00. PLSc = partial least squares correlation. AD, Alzheimer’s Disease; ALS, Amyotrophic lateral sclerosis; CVD, Cerebrovascular disease; FTD, Frontotemporal disease; MCI, Mild Cognitive Impairment; PD, Parkinson’s disease.

Elastic net models

Table 5 Psychotic Subsyndrome analyses

	1000 (70/500)	0.0692 (22/500)	0.0724 (29/500)	0.0631 (35/500)	0.0832 (23/500)	0.0575 (32/500)	0.0661 (28/500)	0.0603 (31/500)
(Intercept)	0.757	3.505	3.254	3.974	2.455	4.402	3.745	4.193
Age	0	-0.010	-0.009	-0.011	-0.007	-0.012	-0.010	-0.012
Sex(female)	0	-0.209	-0.200	-0.226	-0.172	-0.241	-0.217	-0.233
MoCA TOTAL	0	-0.006	-0.005	-0.008	-0.001	-0.009	-0.007	-0.009
LH PARS-ORBITALIS THICKNESS	0	0.153	0.111	0.230	0.000	0.302	0.192	0.267
LH POSTERIOR CINGULATE THICKNESS	0	-0.040	-0.031	-0.056	0.000	-0.071	-0.048	-0.064
LH PRECUNEUS THICKNESS	0	-0.115	-0.091	-0.160	-0.019	-0.201	-0.138	-0.181
RH CAUDAL ANTERIOR CINGULATE THICKNESS	0	-0.021	-0.008	-0.045	-0.000	-0.066	-0.033	-0.056
RH ISTHMUS CINGULATE THICKNESS	0	-0.090	-0.082	-0.104	-0.048	-0.118	-0.097	-0.111
RH PARS-TRIANGULARIS THICKNESS	0	-0.292	-0.258	-0.356	-0.155	-0.414	-0.325	-0.386
RBGT WMH	0	0.116	0.104	0.129	0.075	0.144	0.121	0.137

Row names indicate variables selected, column names indicate the lambda parameter and how many times out of 500 repeats that the lambda parameter had the lowest mean square error for our repeated cross-validation. Values in the cells are coefficients from the full data sample for the corresponding selected variables (rows) under the penalisation parameter (columns). MoCA = Montreal Cognitive Assessment; LH = Left Hemisphere; RBGT WMH = Right Basal Ganglia/Thalamus White Matter Hyperintensities; RH = Right Hemisphere.

Table 6 Apathy Subsyndrome analyses

	0.0661 (25/500)	0.0832 (28/500)	0.0794 (50/500)	0.0955 (28/500)	0.0759 (40/500)	0.0724 (38/500)	0.0871 (55/500)
(Intercept)	8.188	7.115	7.338	6.430	7.550	7.767	6.893
AGE	-0.017	-0.013	-0.014	-0.010	-0.014	-0.015	-0.012
Sex(female)	-0.030	0.000	-0.006	0.000	-0.013	-0.019	0.000
MoCA TOTAL	-0.059	-0.054	-0.055	-0.051	-0.057	-0.058	-0.053
LH CUNEUS THICKNESS	-0.042	0.000	0.000	0.000	0.000	-0.013	0.000
LH ROSTRAL MIDDLE FRONTAL THICKNESS	-0.494	-0.450	-0.460	-0.405	-0.470	-0.478	-0.439

LH FRONTALPOLE THICKNESS	-0.097	-0.055	-0.065	-0.018	-0.074	-0.082	-0.043
LH TRANSVERSETEMPORAL THICKNESS	-0.080	-0.017	-0.034	0.000	-0.051	-0.064	0.000
RH ENTORHINAL THICKNESS	-0.146	-0.108	-0.116	-0.079	-0.124	-0.131	-0.099
RH ISTHMUS CINGULATE THICKNESS	-0.055	-0.008	-0.018	0.000	-0.028	-0.037	0.000
RH MEDIAL ORBITOFRONTAL THICKNESS	-0.040	-0.009	-0.016	0.000	-0.023	-0.029	-0.002
RH MIDDLE TEMPORAL THICKNESS	-0.454	-0.475	-0.471	-0.491	-0.467	-0.464	-0.482
RH PARS-OPERCULARIS THICKNESS	-0.097	-0.045	-0.057	-0.008	-0.069	-0.080	-0.033
RH PARS-TRIANGULARIS THICKNESS	-0.509	-0.514	-0.513	-0.496	-0.511	-0.510	-0.511
RH TRANSVERSETEMPORAL THICKNESS	-0.019	0.000	0.000	0.000	0.000	-0.001	0.000
LF WMH	-0.023	-0.005	-0.009	0.000	-0.012	-0.016	-0.001

Row names indicate variables selected, column names indicate the lambda parameter and how many times out of 500 repeats that the lambda parameter had the lowest mean square error for our repeated cross-validation. Values in the cells are coefficients from the full data sample for the corresponding selected variables (rows) under the penalisation parameter (columns). MoCA = Montreal Cognitive Assessment; LH = Left Hemisphere; LF WMH = Left Frontal White Matter Hyperintensities; RH = Right Hemisphere.

Table 7 Affective Subsyndrome analyses

	1000 (89/500)	0.0525 (44/500)	0.0479 (24/500)	0.0631 (34/500)	0.0661 (31/500)	0.0603 (34/500)	0.0575 (48/500)	0.0549 (42/500)
(Intercept)	0.800	3.419	3.553	3.124	3.046	3.200	3.275	3.348
AGE	0.000	-0.008	-0.009	-0.006	-0.006	-0.007	-0.007	-0.008
Sex(female)	0.000	-0.121	-0.134	-0.090	-0.082	-0.098	-0.106	-0.113
Sex(Male)	0.000	0.009	0.011	-0.004	0.003	0.006	0.007	0.008
MoCA TOTAL	0.000	-0.033	-0.034	-0.029	-0.027	-0.030	-0.031	-0.032
LH LATERAL OCCIPITAL THICKNESS	0.000	0.614	0.657	0.519	0.492	0.544	0.566	0.591
LH LATERAL ORBITOFRONTAL THICKNESS	0.000	0.345	0.420	0.173	0.127	0.217	0.261	0.305
LH LINGUAL THICKNESS	0.000	0.424	0.442	0.384	0.375	0.393	0.405	0.414

LH PERICALCARINE THICKNESS	0.000	0.111	0.140	0.040	0.019	0.059	0.078	0.095
LH POSTERIOR CINGULATE THICKNESS	0.000	-0.118	-0.146	-0.048	-0.027	-0.067	-0.086	-0.103
LH SUPERIOR TEMPORAL THICKNESS	0.000	0.000	-0.002	0.000	0.000	0.000	0.000	0.000
RH CAUDAL ANTERIOR CINGULATE THICKNESS	0.000	-0.279	-0.299	-0.233	-0.218	-0.246	-0.258	-0.269
RH MIDDLE TEMPORAL THICKNESS	0.000	-0.019	-0.035	0.000	0.000	0.000	0.000	-0.009
RH PARS-TRIANGULARIS THICKNESS	0.000	-0.726	-0.761	-0.633	-0.602	-0.622	-0.687	-0.707
RH TEMPORAL POLE THICKNESS	0.000	-0.107	-0.122	-0.072	-0.059	-0.083	-0.091	-0.100
RH INSULA THICKNESS	0.000	-0.040	-0.060	0.000	0.000	-0.004	-0.018	-0.028
RP WMH	0.000	-0.002	-0.005	0.000	0.000	0.000	0.000	0.000
LO WMH	0.000	-0.050	-0.055	-0.036	-0.032	-0.040	-0.044	-0.048
RBGT WMH	0.000	0.197	0.211	0.169	0.161	0.176	0.183	0.190

Row names indicate variables selected, column names indicate the lambda parameter and how many times out of 500 repeats that the lambda parameter had the lowest mean square error for our repeated cross-validation. Values in the cells are coefficients from the full data sample for the corresponding selected variables (rows) under the penalisation parameter (columns). MoCA = Montreal Cognitive Assessment; LH = Left Hemisphere; LO WMH = Left Occipital White Matter Hyperintensities; RBGT WMH = Right Basal Ganglia/Thalamus White Matter Hyperintensities; RH = Right Hemisphere.

Table 8 Hyperactivity Subsyndrome analyses

	0.1514 (32/500)	0.1905 (30/500)	0.1738 (56/500)	0.1445 (29/500)	0.1585 (30/500)	0.1659 (54/500)	0.1819 (51/500)
(Intercept)	8.521	7.047	7.636	8.876	8.179	7.911	7.348
MoCA TOTAL	-0.067	-0.057	-0.061	-0.069	-0.065	-0.063	-0.059
LH FUSIFORM THICKNESS	-0.022	0.000	0.000	-0.034	-0.010	-0.001	0.000
LH ROSTRAL ANTERIOR CINGULATE THICKNESS	-0.174	-0.138	-0.154	-0.180	-0.167	-0.161	-0.146
LH SUPERIOR TEMPORAL THICKNESS	-0.372	-0.360	-0.369	-0.369	-0.373	-0.373	-0.364
LH INSULA THICKNESS	-0.057	-0.047	-0.055	-0.051	-0.061	-0.058	-0.051
RH CAUDAL ANTERIOR CINGULATE THICKNESS	-0.436	-0.308	-0.362	-0.460	-0.412	-0.387	-0.336
RH LATERAL ORBITOFRONTAL THICKNESS	-0.158	-0.174	-0.169	-0.155	-0.163	-0.166	-0.171
RH MEDIAL ORBITOFRONTAL THICKNESS	-0.244	-0.128	-0.177	-0.264	-0.222	-0.643	-0.153

RH PARS-TRIANGULARIS THICKNESS	-0.698	-0.558	-0.616	-0.724	-0.670	-0.593	-0.587
RH TEMPORAL POLE THICKNESS	-0.077	-0.047	-0.060	-0.081	-0.072	-0.067	-0.054
RBGT WMH	0.011	0.000	0.000	0.024	0.000	0.000	0.000

Row names indicate variables selected, column names indicate the lambda parameter and how many times out of 500 repeats that the lambda parameter had the lowest mean square error for our repeated cross-validation. Values in the cells are coefficients from the full data sample for the corresponding selected variables (rows) under the penalisation parameter (columns). MoCA = Montreal Cognitive Assessment; LH = Left Hemisphere; RBGT WMH = Right Basal Ganglia/Thalamus White Matter Hyperintensities; RH = Right Hemisphere.

Partial Least Squares Correlation (PLSc)

Table 9 Bootstrap ratios for the NPS Subsyndromes

	Component 1
Psychosis	1.202
Apathy	5.029
Affective	1.429
Hyperactivity	4.757

Table 10 Bootstrap ratios for all other variables (only those above magnitude of 2 are shown)

	Component 1
MoCA TOTAL	-4.57
Sex(female)	-2.11
LH PARS-TRIANGULARIS THICKNESS	-3.25
LH POSTERIOR CINGULATE THICKNESS	-2.53
LH ROSTRAL ANTERIOR CINGULATE THICKNESS	-2.52
LH SUPERIOR FRONTAL THICKNESS	-3.39
LH INSULA THICKNESS	-3.44
LH PRECUNEUS THICKNESS	-2.75
LH PARAHIPPOCAMPAL THICKNESS	-2.68
LH FUSIFORM THICKNESS	-2.86
LH TEMPORAL POLE THICKNESS	-2.39
LH SUPERIOR TEMPORAL THICKNESS	-3.83
LH MIDDLE TEMPORAL THICKNESS	-3.19
LH PARACENTRAL THICKNESS	-2.43
LH ROSTRAL MIDDLE FRONTAL THICKNESS	-3.58

LH POST CENTRAL THICKNESS	-2.24
LH PARS-OPERCULARIS THICKNESS	-2.64
LH MEDIAL ORBITOFRONTAL THICKNESS	-2.15
LH CAUDAL MIDDLE FRONTAL THICKNESS	-3.09
LH FRONTAL POLE THICKNESS	-2.40
LH TRANSVERSE TEMPORAL THICKNESS	-3.12
LH ENTORHINAL THICKNESS	-2.69
LH ISTHMUS CINGULATE THICKNESS	-2.32
LH INFERIOR PARIETAL THICKNESS	-2.02
LH INFERIOR TEMPORAL THICKNESS	-2.69
RH CAUDAL ANTERIOR CINGULATE THICKNESS	-2.49
RH ENTORHINAL THICKNESS	-3.19
RH PRECUNEUS THICKNESS	-2.77
RH INFERIOR PARIETAL THICKNESS	-2.22
RH CAUDAL MIDDLE FRONTAL THICKNESS	-3.18
RH MEDIAL ORBITOFRONTAL THICKNESS	-2.51
RH LATERAL ORBITOFRONTAL THICKNESS	-3.06
RH INFERIOR TEMPORAL THICKNESS	-3.02
RH MIDDLE TEMPORAL THICKNESS	-4.35
RH PARS-ORBITALIS THICKNESS	-2.54
RH ROSTRAL ANTERIOR CINGULATE THICKNESS	-2.03
RH SUPERIOR TEMPORAL THICKNESS	-3.42
RH SUPRAMARGINAL THICKNESS	-2.37
RH FRONTAL POLE THICKNESS	-2.49
RH TEMPORAL POLE THICKNESS	-2.99
RH PARAHIPPOCAMPAL THICKNESS	-3.05
RH LATERAL OCCIPITAL THICKNESS	-2.35
RH LINGUAL THICKNESS	-2.56
RH FUSIFORM THICKNESS	-3.32
RH ISTHMUS CINGULATE THICKNESS	-2.89
RH PARS-OPERCULARIS THICKNESS	-2.29
RH PARS-TRIANGULARIS THICKNESS	-3.54
RH POSTERIOR CINGULATE THICKNESS	-2.65
RH ROSTRAL MIDDLE FRONTAL THICKNESS	-3.23
RH SUPERIOR FRONTAL THICKNESS	-3.78
RH TRANSVERSE TEMPORAL THICKNESS	-2.73
RH INSULA THICKNESS	-2.95

LH = Left Hemisphere; RH = Right Hemisphere; MoCA = Montreal Cognitive Assessment.